{"title":"Nano-golden adjuvant-polymersomes empower tumor photothermal-immunotherapy","authors":"Zhiwei Sun, Jingyi Wang, Beibei Guo, Songsong Zhao, Shiyu Miao, Mingyu Xia, Zhiyuan Zhong, Fenghua Meng","doi":"10.1016/j.jconrel.2025.113976","DOIUrl":null,"url":null,"abstract":"The integration of photothermal therapy with immunotherapy represent a potential treatment for tumor patients. Here, we demonstrate that nano‑golden adjuvant-polymersomes (nGAP) with gold nanoclusters imbedded in the membrane and immunoadjuvant poly(I:C) encapsulated within the aqueous core empower tumor photothermal-immunotherapy. Upon near-infrared irradiation, nGAP elicits a strong photothermal effect on tumor cells, driving immunogenic cell death and activating dendritic cells. In murine LLC lung tumor models, a single session of irradiation following intratumoral injection of nGAP led to an impressive 83 % cure rate, which further increased to 100 % complete regression by equipping cRGD peptide on the polymersome surface and combining with anti-CTLA-4 antibody. Furthermore, the cured mice exhibited effective resistance to subsequent tumor re-challenges. Our findings also reveal that nGAP yields explicit abscopal effects, supporting the development of systemic and long-lasting anticancer immunity. nGAP presents an interesting therapeutic modality capable of effectively ablating both primary solid tumors and their metastatic counterparts.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"7 1","pages":""},"PeriodicalIF":10.5000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jconrel.2025.113976","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
The integration of photothermal therapy with immunotherapy represent a potential treatment for tumor patients. Here, we demonstrate that nano‑golden adjuvant-polymersomes (nGAP) with gold nanoclusters imbedded in the membrane and immunoadjuvant poly(I:C) encapsulated within the aqueous core empower tumor photothermal-immunotherapy. Upon near-infrared irradiation, nGAP elicits a strong photothermal effect on tumor cells, driving immunogenic cell death and activating dendritic cells. In murine LLC lung tumor models, a single session of irradiation following intratumoral injection of nGAP led to an impressive 83 % cure rate, which further increased to 100 % complete regression by equipping cRGD peptide on the polymersome surface and combining with anti-CTLA-4 antibody. Furthermore, the cured mice exhibited effective resistance to subsequent tumor re-challenges. Our findings also reveal that nGAP yields explicit abscopal effects, supporting the development of systemic and long-lasting anticancer immunity. nGAP presents an interesting therapeutic modality capable of effectively ablating both primary solid tumors and their metastatic counterparts.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.